Scientists are increasingly focused on retatrutide, a promising drug developed by Eli Lilly, as a potential advance in weight reduction . Distinct from many earlier approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, substances that affect appetite and glucose regulatio